

Matteo Simonelli

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/4915859/matteo-simonelli-publications-by-year.pdf>

Version: 2024-04-24

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

74
papers

1,702
citations

23
h-index

39
g-index

80
ext. papers

2,161
ext. citations

4.6
avg. IF

4.35
L-index

| # | Paper | IF | Citations |
|----|---|------|-----------|
| 74 | Quality of life of adult cancer survivors enrolled in Humanitas Research Hospital's survivorship care model.. <i>Supportive Care in Cancer</i> , 2022 , 1 | 3.9 | |
| 73 | Phase Ib/II study of ceritinib in combination with ribociclib in patients with ALK-rearranged non-small cell lung cancer.. <i>Lung Cancer</i> , 2022 , 166, 170-177 | 5.9 | 0 |
| 72 | Definition of the Prognostic Role of MGMT Promoter Methylation Value by Pyrosequencing in Newly Diagnosed IDH Wild-Type Glioblastoma Patients Treated with Radiochemotherapy: A Large Multicenter Study. <i>Cancers</i> , 2022 , 14, 2425 | 6.6 | |
| 71 | Immunotherapeutic early-phase clinical trials and malignant gliomas: A single-center experience and comprehensive immunophenotyping of circulating leukocytes.. <i>Neuro-Oncology Advances</i> , 2021 , 3, vda160 | 0.9 | 0 |
| 70 | NKG2A expression identifies a subset of human V α T β cells exerting the highest antitumor effector functions. <i>Cell Reports</i> , 2021 , 37, 109871 | 10.6 | 2 |
| 69 | Checkpoint Inhibitors as High-Grade Gliomas Treatment: State of the Art and Future Perspectives. <i>Journal of Clinical Medicine</i> , 2021 , 10, | 5.1 | 8 |
| 68 | Role of 11C Methionine Positron Emission Tomography (11CMETPET) for Surgery and Radiation Therapy Planning in Newly Diagnosed Glioblastoma Patients Enrolled into a Phase II Clinical Study. <i>Journal of Clinical Medicine</i> , 2021 , 10, | 5.1 | 1 |
| 67 | Depatuzumab Mafodotin (Depatux-M) Plus Temozolomide in Recurrent Glioblastoma Patients: Real-World Experience from a Multicenter Study of Italian Association of Neuro-Oncology (AINO). <i>Cancers</i> , 2021 , 13, | 6.6 | 8 |
| 66 | Association of supratotal resection with progression-free survival, malignant transformation, and overall survival in lower-grade gliomas. <i>Neuro-Oncology</i> , 2021 , 23, 812-826 | 1 | 23 |
| 65 | Prognostic relevance of temporal muscle thickness as a marker of sarcopenia in patients with glioblastoma at diagnosis. <i>European Radiology</i> , 2021 , 31, 4079-4086 | 8 | 7 |
| 64 | The 70-year-old newly diagnosed glioblastoma patients are older than the 65-year-old? Outcome evaluation of the two categories in a matched case control study with propensity score balancing. <i>Radiotherapy and Oncology</i> , 2021 , 156, 49-55 | 5.3 | 1 |
| 63 | Risks of molecular targeted therapies to fertility and safety during pregnancy: a review of current knowledge and future needs. <i>Expert Opinion on Drug Safety</i> , 2021 , 20, 503-521 | 4.1 | 1 |
| 62 | COVID-19 lung injury as a primer for immune checkpoint inhibitors (ICIs)-related pneumonia in a patient affected by squamous head and neck carcinoma treated with PD-L1 blockade: a case report 2021 , 9, | | 5 |
| 61 | First-In-Human Phase I Study of a Next-Generation, Oral, TGF β Receptor 1 Inhibitor, LY3200882, in Patients with Advanced Cancer. <i>Clinical Cancer Research</i> , 2021 , | 12.9 | 2 |
| 60 | Treatment with pembrolizumab in programmed death ligand 1-positive recurrent glioblastoma: Results from the multicohort phase 1 KEYNOTE-028 trial. <i>Cancer</i> , 2021 , 127, 1620-1629 | 6.4 | 11 |
| 59 | Conducting Phase I Trials During the SARS-Coronavirus-2 Outbreak: About Science and Care. <i>Frontiers in Oncology</i> , 2020 , 10, 926 | 5.3 | 3 |
| 58 | Cerebrospinal fluid tumor DNA for liquid biopsy in glioma patients's management: Close to the clinic?. <i>Critical Reviews in Oncology/Hematology</i> , 2020 , 146, 102879 | 7 | 8 |

| | | | |
|----|---|------|-----|
| 57 | Is IDH status the only factor predicting prognosis in newly diagnosed anaplastic glioma patients? Outcome evaluation and prognostic factor analysis in a single-institution large series. <i>Journal of Neurosurgery</i> , 2020 , 1-14 | 3.2 | 5 |
| 56 | Treatment of patients with glioma during the COVID-19 pandemic: what we learned and what we take home for the future. <i>Neurosurgical Focus</i> , 2020 , 49, E10 | 4.2 | 4 |
| 55 | Neuro-Oncology During the COVID-19 Outbreak: A Hopeful Perspective at the End of the Italian Crisis. <i>Frontiers in Medicine</i> , 2020 , 7, 594610 | 4.9 | 5 |
| 54 | Role of myeloid cells in the immunosuppressive microenvironment in gliomas. <i>Immunobiology</i> , 2020 , 225, 151853 | 3.4 | 25 |
| 53 | Mismatch-Repair Protein Expression in High-Grade Gliomas: A Large Retrospective Multicenter Study. <i>International Journal of Molecular Sciences</i> , 2020 , 21, | 6.3 | 6 |
| 52 | Pembrolizumab Activity in Recurrent High-Grade Gliomas with Partial or Complete Loss of Mismatch Repair Protein Expression: A Monocentric, Observational and Prospective Pilot Study. <i>Cancers</i> , 2020 , 12, | 6.6 | 19 |
| 51 | Lower Grade Gliomas: Relationships Between Metabolic and Structural Imaging with Grading and Molecular Factors. <i>World Neurosurgery</i> , 2019 , 126, e270-e280 | 2.1 | 8 |
| 50 | Pembrolizumab (Pem) in recurrent high-grade glioma (HGG) patients (PTS) with mismatch repair deficiency (MMRd): An observational study.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 2043-2043 | 2.2 | 1 |
| 49 | Is supratotal resection achievable in low-grade gliomas? Feasibility, putative factors, safety, and functional outcome. <i>Journal of Neurosurgery</i> , 2019 , 132, 1692-1705 | 3.2 | 18 |
| 48 | High-grade gliomas (HGGs) and immunotherapeutic early-phase clinical trials (ieCTs): A single-center experience.. <i>Journal of Clinical Oncology</i> , 2019 , 37, e13512-e13512 | 2.2 | |
| 47 | Primary ovarian insufficiency associated with pazopanib therapy in a breast angiosarcoma patient: A CARE-compliant case report. <i>Medicine (United States)</i> , 2019 , 98, e18089 | 1.8 | 6 |
| 46 | Hypofractionated radiation therapy (HFRT) versus conventional fractionated radiation therapy (CRT) for newly diagnosed glioblastoma patients. A propensity score matched analysis. <i>Radiotherapy and Oncology</i> , 2018 , 127, 108-113 | 5.3 | 10 |
| 45 | Checkpoint inhibitors as treatment for malignant gliomas: "A long way to the top". <i>Cancer Treatment Reviews</i> , 2018 , 69, 121-131 | 14.4 | 27 |
| 44 | Phase II Study of Everolimus in Patients With Thymoma and Thymic Carcinoma Previously Treated With Cisplatin-Based Chemotherapy. <i>Journal of Clinical Oncology</i> , 2018 , 36, 342-349 | 2.2 | 70 |
| 43 | Is surgical resection useful in elderly newly diagnosed glioblastoma patients? Outcome evaluation and prognostic factors assessment. <i>Acta Neurochirurgica</i> , 2018 , 160, 1779-1787 | 3 | 12 |
| 42 | Prognostic value of molecular and imaging biomarkers in patients with supratentorial glioma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017 , 44, 1155-1164 | 8.8 | 58 |
| 41 | Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with recurrent carcinoma of the anal canal. <i>Annals of Oncology</i> , 2017 , 28, 1036-1041 | 10.3 | 138 |
| 40 | Prognostic and predictive role of [F]fluorodeoxyglucose positron emission tomography (FDG-PET) in patients with unresectable malignant pleural mesothelioma (MPM) treated with up-front pemetrexed-based chemotherapy. <i>Cancer Medicine</i> , 2017 , 6, 2287-2296 | 4.8 | 17 |

| | | | |
|----|--|------|----|
| 39 | Maximize surgical resection beyond contrast-enhancing boundaries in newly diagnosed glioblastoma multiforme: is it useful and safe? A single institution retrospective experience. <i>Journal of Neuro-Oncology</i> , 2017 , 135, 129-139 | 4.8 | 72 |
| 38 | Role of surgical resection in recurrent glioblastoma: prognostic factors and outcome evaluation in an observational study. <i>Journal of Neuro-Oncology</i> , 2017 , 131, 377-384 | 4.8 | 13 |
| 37 | Neutrophils in Gliomas. <i>Frontiers in Immunology</i> , 2017 , 8, 1349 | 8.4 | 59 |
| 36 | Are three weeks hypofractionated radiation therapy (HFRT) comparable to six weeks for newly diagnosed glioblastoma patients? Results of a phase II study. <i>Oncotarget</i> , 2017 , 8, 67696-67708 | 3.3 | 12 |
| 35 | Infertility risk and teratogenicity of molecularly targeted anticancer therapy: A challenging issue. <i>Critical Reviews in Oncology/Hematology</i> , 2016 , 107, 1-13 | 7 | 12 |
| 34 | Phase I study of PF-03446962, a fully human monoclonal antibody against activin receptor-like kinase-1, in patients with hepatocellular carcinoma. <i>Annals of Oncology</i> , 2016 , 27, 1782-7 | 10.3 | 23 |
| 33 | Pathological characterization of nivolumab-related liver injury in a patient with glioblastoma. <i>Immunotherapy</i> , 2016 , 8, 1363-1369 | 3.8 | 28 |
| 32 | Value of Surgical Resection in Patients with Newly Diagnosed Grade III Glioma Treated in a Multimodal Approach: Surgery, Chemotherapy and Radiotherapy. <i>Annals of Surgical Oncology</i> , 2016 , 23, 3040-6 | 3.1 | 25 |
| 31 | Targeted therapy for thymic epithelial tumors: a new horizon? Review of the literature and two cases reports. <i>Future Oncology</i> , 2015 , 11, 1223-32 | 3.6 | 5 |
| 30 | Multimodality therapy approaches, local and systemic treatment, compared with chemotherapy alone in recurrent glioblastoma. <i>BMC Cancer</i> , 2015 , 15, 486 | 4.8 | 18 |
| 29 | Phase 1 trial of tivantinib in combination with sorafenib in adult patients with advanced solid tumors. <i>Investigational New Drugs</i> , 2015 , 33, 159-68 | 4.3 | 40 |
| 28 | Imaging biomarkers in primary brain tumours. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2015 , 42, 597-612 | 8.8 | 18 |
| 27 | Investigation on the role of integrated PET/MRI for target volume definition and radiotherapy planning in patients with high grade glioma. <i>Radiotherapy and Oncology</i> , 2014 , 112, 425-9 | 5.3 | 34 |
| 26 | Prognostic factors in elderly patients with malignant pleural mesothelioma: results of a multicenter survey. <i>British Journal of Cancer</i> , 2014 , 111, 220-6 | 8.7 | 28 |
| 25 | Vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma. <i>Lung Cancer</i> , 2014 , 84, 265-70 | 5.9 | 39 |
| 24 | Phase II study of everolimus in patients with thymoma and thymic carcinoma previously treated with cisplatin-based chemotherapy.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 7527-7527 | 2.2 | 14 |
| 23 | A Phase-1b study of tivantinib (ARQ 197) in adult patients with hepatocellular carcinoma and cirrhosis. <i>British Journal of Cancer</i> , 2013 , 108, 21-4 | 8.7 | 66 |
| 22 | Reproducibility of the WHO classification of thymomas: practical implications. <i>Lung Cancer</i> , 2013 , 79, 236-41 | 5.9 | 30 |

| | | | |
|----|--|------|-----|
| 21 | Phase I pharmacokinetic and pharmacodynamic study of lapatinib in combination with sorafenib in patients with advanced refractory solid tumors. <i>European Journal of Cancer</i> , 2013 , 49, 989-98 | 7.5 | 12 |
| 20 | Tivantinib: a new promising mesenchymal-epithelial transition factor inhibitor in the treatment of hepatocellular carcinoma. <i>Future Oncology</i> , 2013 , 9, 153-65 | 3.6 | 15 |
| 19 | Phase I and pharmacodynamic study of high-dose NGR-hTNF in patients with refractory solid tumours. <i>British Journal of Cancer</i> , 2013 , 108, 58-63 | 8.7 | 15 |
| 18 | Second-line chemotherapy in malignant pleural mesothelioma: results of a retrospective multicenter survey. <i>Lung Cancer</i> , 2012 , 75, 360-7 | 5.9 | 73 |
| 17 | Intensified chemotherapy with stem-cell rescue in germ-cell tumors. <i>Annals of Oncology</i> , 2012 , 23, 815-22 | 10.3 | 15 |
| 16 | Safety and efficacy of MET inhibitor tivantinib (ARQ 197) combined with sorafenib in patients (pts) with hepatocellular carcinoma (HCC) from a phase I study.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 4117-4127 | 11.7 | 6 |
| 15 | Temozolomide combined with radiotherapy in the treatment of recurrent cranial meningioma previously treated with multiple surgical resections and two sessions of radiosurgery: a case report and literature review. <i>Tumori</i> , 2012 , 98, 67e-71e | 1.7 | 2 |
| 14 | Retreatment with pemetrexed-based chemotherapy in patients with malignant pleural mesothelioma. <i>Lung Cancer</i> , 2011 , 72, 73-7 | 5.9 | 99 |
| 13 | Thymidylate synthase and excision repair cross-complementing group-1 as predictors of responsiveness in mesothelioma patients treated with pemetrexed/carboplatin. <i>Clinical Cancer Research</i> , 2011 , 17, 2581-90 | 12.9 | 78 |
| 12 | Advances in the biology of malignant pleural mesothelioma. <i>Cancer Treatment Reviews</i> , 2011 , 37, 543-581 | 14.4 | 79 |
| 11 | Treatment of malignant pleural mesothelioma: current status and future directions. <i>Clinical Investigation</i> , 2011 , 1, 999-1018 | | 1 |
| 10 | Response to sunitinib in an adult patient with rhabdoid renal cell carcinoma. <i>Journal of Clinical Oncology</i> , 2011 , 29, e529-31 | 2.2 | 7 |
| 9 | Expression of the Transcription Factor HEY1 in Glioblastoma: A Preliminary Clinical Study. <i>Tumori</i> , 2010 , 96, 97-102 | 1.7 | 18 |
| 8 | Phase II study of asparagine-glycine-arginine-human tumor necrosis factor alpha, a selective vascular targeting agent, in previously treated patients with malignant pleural mesothelioma. <i>Journal of Clinical Oncology</i> , 2010 , 28, 2604-11 | 2.2 | 101 |
| 7 | Correlation of microvascular fractal dimension with positron emission tomography [(11)C]-methionine uptake in glioblastoma multiforme: preliminary findings. <i>Microvascular Research</i> , 2010 , 80, 267-73 | 3.7 | 22 |
| 6 | Insulin-like growth factor-1 receptor and phosphorylated AKT-serine 473 expression in 132 resected thymomas and thymic carcinomas. <i>Cancer</i> , 2010 , 116, 4686-95 | 6.4 | 43 |
| 5 | Thymoma Associated with Myasthenia and Autonomic anti-Hu Paraneoplastic Neuropathy. <i>Tumori</i> , 2009 , 95, 243-247 | 1.7 | 15 |
| 4 | Future developments in the management of malignant pleural mesothelioma. <i>Expert Review of Anticancer Therapy</i> , 2009 , 9, 453-67 | 3.5 | 18 |

| | | | |
|---|--|-----|----|
| 3 | Administration of temozolomide during and after radiotherapy for newly diagnosed high-grade gliomas excluding glioblastoma multiforme. <i>Journal of Neuro-Oncology</i> , 2007 , 81, 323-5 | 4.8 | |
| 2 | High-dose chemotherapy followed by autologous hematopoietic stem-cell transplantation for the treatment of solid tumors in adults: a critical review. <i>Current Stem Cell Research and Therapy</i> , 2007 , 2, 65-82 | 3.6 | 19 |
| 1 | Herpes infections in breast cancer patients treated with adjuvant chemotherapy. <i>Oncology</i> , 2006 , 71, 164-7 | 3.6 | 16 |